COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on “Two-Path Unifying Theory” of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy
Open Access
- 1 June 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Vascular Health and Risk Management
- Vol. ume 17, 273-298
- https://doi.org/10.2147/vhrm.s299357
Abstract
COVID-19 sepsis is characterized by acute respiratory distress syndrome (ARDS) as a consequence of pulmonary tropism of the virus and endothelial heterogeneity of the host. ARDS is a phenotype among patients with multiorgan dysfunction syndrome (MODS) due to disseminated vascular microthrombotic disease (VMTD). In response to the viral septicemia, the host activates the complement system which produces terminal complement complex C5b-9 to neutralize pathogen. C5b-9 causes pore formation on the membrane of host endothelial cells (ECs) if CD59 is underexpressed. Also, viral S protein attraction to endothelial ACE2 receptor damages ECs. Both affect ECs and provoke endotheliopathy. Disseminated endotheliopathy activates two molecular pathways: inflammatory and microthrombotic. The former releases inflammatory cytokines from ECs, which lead to inflammation. The latter initiates endothelial exocytosis of unusually large von Willebrand factor (ULVWF) multimers and FVIII from Weibel–Palade bodies. If ADAMTS13 is insufficient, ULVWF multimers activate intravascular hemostasis of ULVWF path. In activated ULVWF path, ULVWF multimers anchored to damaged endothelial cells recruit circulating platelets and trigger microthrombogenesis. This process produces “microthrombi strings” composed of platelet-ULVWF complexes, leading to endotheliopathy-associated VMTD (EA-VMTD). In COVID-19, microthrombosis initially affects the lungs per tropism causing ARDS, but EA-VMTD may orchestrate more complex clinical phenotypes, including thrombotic thrombocytopenic purpura (TTP)-like syndrome, hepatic coagulopathy, MODS and combined micro-macrothrombotic syndrome. In this pandemic, ARDS and pulmonary thromboembolism (PTE) have often coexisted. The analysis based on two hemostatic theories supports ARDS caused by activated ULVWF path is EA-VMTD and PTE caused by activated ULVWF and TF paths is macrothrombosis. The thrombotic disorder of COVID-19 sepsis is consistent with the notion that ARDS is virus-induced disseminated EA-VMTD and PTE is in-hospital vascular injury-related macrothrombosis which is not directly related to viral pathogenesis. The pathogenesis-based therapeutic approach is discussed for the treatment of EA-VMTD with antimicrothrombotic regimen and the potential need of anticoagulation therapy for coinciding macrothrombosis in comprehensive COVID-19 care.Keywords
This publication has 156 references indexed in Scilit:
- The chemistry and biological activities of N-acetylcysteineBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Unwinding the von Willebrand factor strings puzzleBlood, 2013
- Pulmonary embolism in mechanically ventilated patientsCritical Care Medicine, 2012
- Platelets in Pulmonary Vascular Physiology and PathologyPulmonary Circulation, 2012
- A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13Blood, 2012
- N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and miceJCI Insight, 2011
- Tracheal intubation in the ICU: Life saving or life threatening?Indian Journal of Anaesthesia, 2011
- Disulfide bond reduction of von Willebrand factor by ADAMTS‐13Journal of Thrombosis and Haemostasis, 2010
- Pathophysiology of thrombotic thrombocytopenic purpuraInternational Journal of Hematology, 2010
- Integrin αvβ3 on human endothelial cells binds von Willebrand factor strings under fluid shear stressBlood, 2009